相似文献
1
Cell survival signaling in neuroblastoma.
Anticancer Agents Med Chem. 2013 May;13(4):563-75. doi: 10.2174/1871520611313040005.
2
The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma.
Anticancer Agents Med Chem. 2014 Jan;14(1):46-51. doi: 10.2174/18715206113136660331.
3
Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
BMC Cancer. 2021 Sep 26;21(1):1061. doi: 10.1186/s12885-021-08782-9.
4
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
PLoS One. 2013 Aug 23;8(8):e72967. doi: 10.1371/journal.pone.0072967. eCollection 2013.
5
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Cancer Lett. 2017 Aug 1;400:61-68. doi: 10.1016/j.canlet.2017.04.022. Epub 2017 Apr 26.
6
The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
Curr Cancer Drug Targets. 2009 Sep;9(6):729-37. doi: 10.2174/156800909789271521.
7
Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Oncogene. 2008 May 1;27(20):2910-22. doi: 10.1038/sj.onc.1210938. Epub 2007 Nov 19.
8
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
PLoS One. 2012;7(10):e47109. doi: 10.1371/journal.pone.0047109. Epub 2012 Oct 8.
9
The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Oncotarget. 2017 Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268.
10
Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
Mol Carcinog. 2015 Jan;54(1):9-23. doi: 10.1002/mc.22070. Epub 2013 Jul 19.
引用本文的文献
1
Revisiting Neuroblastoma: Nrf2, NF-κB and Phox2B as a Promising Network in Neuroblastoma.
Curr Issues Mol Biol. 2024 Apr 6;46(4):3193-3208. doi: 10.3390/cimb46040200.
2
ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo.
Cancers (Basel). 2022 Nov 10;14(22):5534. doi: 10.3390/cancers14225534.
3
The significance of PAK4 in signaling and clinicopathology: A review.
Open Life Sci. 2022 Jun 20;17(1):586-598. doi: 10.1515/biol-2022-0064. eCollection 2022.
4
RRS1 knockdown inhibits the proliferation of neuroblastoma cell via PI3K/Akt/NF-κB pathway.
Pediatr Res. 2025 Jan;97(1):202-212. doi: 10.1038/s41390-022-02073-0. Epub 2022 May 6.
5
Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.
Pharmacol Rep. 2021 Feb;73(1):211-226. doi: 10.1007/s43440-020-00162-7. Epub 2020 Oct 8.
6
GO Nanosheets: Promising Nano Carrier for the S29, 1-(2-Chloro-2-(4-chlorophenyl-ethyl)--(4-fluorobenzyl)-1-pyrazolo[3,4-d] pyrimidin-4-amine, Therapeutic Agent in Neuroblastoma.
Int J Mol Sci. 2020 Sep 3;21(17):6430. doi: 10.3390/ijms21176430.
7
Licochalcone A Inhibits and Gene Expression and Hypoxic Growth of Human Tumor Cell Lines.
Int J Mol Sci. 2020 Jan 13;21(2):506. doi: 10.3390/ijms21020506.
8
Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.
Cancer Biol Ther. 2019;20(12):1416-1429. doi: 10.1080/15384047.2019.1647049. Epub 2019 Sep 1.
9
IGF1R facilitates epithelial-mesenchymal transition and cancer stem cell properties in neuroblastoma via the STAT3/AKT axis.
Cancer Manag Res. 2019 Jun 12;11:5459-5472. doi: 10.2147/CMAR.S196862. eCollection 2019.
10
Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation.
Int J Mol Sci. 2019 Mar 7;20(5):1170. doi: 10.3390/ijms20051170.
本文引用的文献
1
Measurement of co-localization of objects in dual-colour confocal images.
J Microsc. 1993 Mar;169(3):375-382. doi: 10.1111/j.1365-2818.1993.tb03313.x.
2
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Cancer. 2012 Oct 1;118(19):4795-800. doi: 10.1002/cncr.27459. Epub 2012 Mar 21.
3
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.
Onco Targets Ther. 2012;5:21-9. doi: 10.2147/OTT.S14578. Epub 2012 Mar 2.
4
MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.
Carcinogenesis. 2012 May;33(5):976-85. doi: 10.1093/carcin/bgs114. Epub 2012 Mar 1.
5
A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
Anticancer Agents Med Chem. 2013 May;13(4):532-45. doi: 10.2174/1871520611313040002.
6
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Oncogene. 2012 Dec 13;31(50):5193-200. doi: 10.1038/onc.2012.12. Epub 2012 Jan 30.
7
Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition.
Surgery. 2012 May;151(5):736-44. doi: 10.1016/j.surg.2011.12.014. Epub 2012 Jan 28.
8
Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
BMC Cancer. 2011 Dec 22;11:525. doi: 10.1186/1471-2407-11-525.
9
In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib.
Oncol Rep. 2012 Mar;27(3):734-40. doi: 10.3892/or.2011.1582. Epub 2011 Dec 7.
10
Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells.
Clin Lab. 2011;57(9-10):781-4.
Zotero 插件